Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: jpbrody who wrote (522)	2/4/2000 7:47:00 PM
From: g.w. barnard	Read Replies (1) \| Respond to of 1025

j, nope didn't hear the vcall but did read this today concern s-3 sell registration. gw Subject to completion, dated February 4, 2000 PROSPECTUS 1,700,000 SHARES [LOGO] IGEN INTERNATIONAL, INC. COMMON STOCK This prospectus relates solely to the resale of up to an aggregate of 1,700,000 shares of common stock of IGEN International, Inc. that we may issue to the selling stockholders listed on page 13 of this prospectus. The selling stockholders may sell these shares from time to time in transactions on The Nasdaq National Market, in the over-the-counter market, in negotiated transactions, through put or call option transactions relating to the shares, through short sales of shares or through a combination of these methods. They may sell the shares at market prices prevailing at the time of sale or at negotiated prices. We will not receive any of the proceeds from the sale of the shares being sold by the selling stockholders. We have agreed to bear the expenses incurred in connection with the registration of these shares. The selling stockholders will pay or assume brokerage commissions or similar charges incurred in the sale of these shares of common stock. Our common stock is traded on The Nasdaq National Market under the symbol "IGEN." On February 3, 2000, the closing price for the common stock as reported by Nasdaq was $32.00 per share. PLEASE SEE "RISK FACTORS" BEGINNING ON PAGE 3 FOR A DISCUSSION OF FACTORS YOU SHOULD CONSIDER IN CONNECTION WITH THIS OFFERING. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined that this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is February [ ], 2000.